SCHEMBL15411396

SCHEMBL15411396

CC(=O)Nc1nc2c(-c3cccc(C(F)(F)F)c3)c(C)c(-c3ncnn3-c3ccc(C#N)cn3)cn2n1

nearest known ligand 0.37

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MGAT2 Q10469 4/20 0.37
ADORA2A P29274 2/20 0.37
MC4R P32245 1/20 0.37
MAT2A P31153 1/20 0.36
FYN P06241 1/20 0.36
ELANE P08246 6/20 0.35
LRRK2 Q5S007 1/20 0.35
EGLN2 Q96KS0 1/20 0.35
TOP2A P11388 1/20 0.35
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15411679 0.92 ELANE (0.38) ADORA2AMC4RMAT2AFYNELANE
SCHEMBL15410874 0.84 EGLN2 (0.40) ADORA2AMC4RMAT2AFYNELANE
SCHEMBL15411167 0.83 ELANE (0.38) ADORA2AMC4RMAT2AFYNELANE
SCHEMBL15411069 0.83 EGLN2 (0.42) ADORA2AMC4RMAT2AFYNELANE
SCHEMBL15412053 0.83 EGLN2 (0.38) ADORA2AMC4RMAT2AFYNELANE
SCHEMBL15412140 0.82 MALT1 (0.36) MGAT2ADORA2AMAT2AELANE
SCHEMBL15411629 0.82 ELANE (0.49) ADORA2AMC4RMAT2AFYNELANE
SCHEMBL15412214 0.82 ADORA2A (0.39) ADORA2AMC4RMAT2AFYNELANE
SCHEMBL18043803 0.81 KMT2A (0.45) ADORA2AMAT2AELANEEGLN2KDM4E
SCHEMBL15425572 0.81 ELANE (0.36) MGAT2ADORA2AMAT2AELANELRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2872509-B1 INHIBITION OF ENZYMES CHIESI FARMA SPA (IT) 2016-09-14 EP disclosed
EP-2872509-B1 INHIBITION OF ENZYMES CHIESI FARMA SPA (IT) 2016-09-14 EP disclosed
US-9199984-B2 Inhibition of enzymes CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-01 US disclosed
US-9199984-B2 Inhibition of enzymes CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-01 US disclosed
US-9199984-B2 Inhibition of enzymes CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-01 US disclosed
EP-2872509-A1 INHIBITION OF ENZYMES Chiesi Farmaceutici S.p.A. (IT) 2015-05-20 EP disclosed
US-20140018345-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A (IT) 2014-01-16 US disclosed
US-20140018345-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A (IT) 2014-01-16 US disclosed
US-20140018345-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A (IT) 2014-01-16 US disclosed
WO-2014009425-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A. (IT) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018345-A1 INHIBITION OF ENZYMES SERPINB1, ELANE, MPO MGAT2 1515/4885ADORA2A 1511/4885MC4R 2933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.